However, the majority of HNSCC patients will progress on these agents, highlighting the importance of developing predictive biomarkers to better determine who will benefit from treatment with anti-PD-1/PD-L1 ICIs. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.